NEW YORK – Biotech firm Nuclera said Wednesday it has closed a $42.5 million Series B financing round.
The Cambridge, UK-based firm said it would use the funds to accelerate the development and commercialization of its eProtein desktop bioprinter including developing its capabilities as a proteomics platform.
Investors participating in the round included M&G, Amadeus Capital Partners, E Ink, RT Partners, Future Planet Capital, British Business Bank Future Fund, and G.K. Goh.
The eProtein printer uses Nuclera's eDrop microfluidic technology to synthesize proteins in as little as 24 hours. The company is targeting the device to customers in the pharma, biotech, ag-bio, and synthetic biology fields.
Nuclera initially plans to offer the eProtein system for screening and printing proteins for research and drug discovery but also plans to develop it for protein characterization as part of what the company called "an all-encompassing proteomics platform."
"Our eProtein desktop bioprinter makes it easy for scientists to access the proteins they need in a single day rather than the weeks, months, or even years it currently takes," Michael Chen, cofounder and CEO of Nuclera, said in a statement. "The new financing and partners we are announcing today is a strong vote of confidence in our mission to increase the accessibility of the drug discovery and general bio-innovation process."